Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 124Myeloid 101Lymphoid 100Sarcoma 57Plasma cell 45Dermatologic 36CNS 27Classical hematology 24Genitourinary 21Gynecologic 15Breast 13Other neoplasm 3Thoracic 1Other 1

Conditions

Carcinoma, Non-Small-Cell Lung 6874Lung Neoplasms 5105Small Cell Lung Carcinoma 1166Breast Neoplasms 855Neoplasms 762Colorectal Neoplasms 670Melanoma 566Ovarian Neoplasms 506Neoplasm Metastasis 481Pancreatic Neoplasms 473Adenocarcinoma of Lung 398Stomach Neoplasms 396Prostatic Neoplasms 370Head and Neck Neoplasms 368Carcinoma, Renal Cell 350Esophageal Neoplasms 337Squamous Cell Carcinoma of Head and Neck 325Mesothelioma, Malignant 324Colonic Neoplasms 294Mesothelioma 289Urinary Bladder Neoplasms 262Brain Neoplasms 254Uterine Cervical Neoplasms 243Triple Negative Breast Neoplasms 223Sarcoma 198Endometrial Neoplasms 196Carcinoma, Hepatocellular 186NSCLC 167Pleural Effusion, Malignant 160Kidney Neoplasms 160

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Juvenile × Thoracic × Clear all
NCT00171912 2017-02-23

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Novartis

Phase 2 Completed
38 enrolled
MyeloidOther hematologic neoplasmSarcomaThoracic

Lung Neoplasms, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Dermatofibrosarcoma, Mastocytosis, Systemic, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡